The short answer: yes for some hips, no for others

For patients wondering whether a ChondroFiller injection could spare them a hip replacement, the honest answer has two tracks — and which track applies depends almost entirely on the state of the hip joint at the time of treatment.

For a defined group of patients — those with a focal, well-bordered area of Grade III or IV cartilage damage, healthy surrounding cartilage, and no established widespread osteoarthritis — the evidence suggests ChondroFiller can meaningfully delay, and in some cases avoid, the need for total hip replacement. In a prospective cohort of 26 patients followed for up to five years, 17 of 21 evaluable cases achieved good or excellent outcomes, and only two went on to require hip replacement.

For patients with diffuse or end-stage hip osteoarthritis, the picture is different. Those with Tönnis Grade 2–3 disease fared poorly in the same cohort, and total hip replacement remains the appropriate and proven end-stage option for that group.

The treatment works by recruiting the patient's own progenitor cells into an injectable collagen scaffold — a regenerative mechanism, not a passive cushion — but no mechanism overcomes the wrong patient selection.

In the UK, including Lincolnshire, ChondroFiller carries no NICE appraisal for hip use and is available exclusively on a private basis.

What ChondroFiller does inside the hip joint

Once injected under ultrasound guidance into the hip joint, ChondroFiller — a CE-marked Class III acellular collagen hydrogel manufactured by Meidrix Biomedicals — gels in situ within approximately three to five minutes, settling over the worn articular surface as a structured matrix.

The key distinction from other intra-articular therapies lies in its mechanism. ChondroFiller works through acellular matrix-induced chondrogenesis: rather than delivering repair cells itself, the scaffold creates the biological conditions that draw the patient's own progenitor cells — from the synovium and subchondral bone — into the defect site. A 2025 ex vivo study provided direct evidence of this process, showing a 2.4-fold increase in DNA content within ChondroFiller-treated defects by day 14 compared with untreated controls. That finding confirms active cell recruitment rather than passive space-filling.

This separates ChondroFiller meaningfully from the two most common hip injection alternatives. Hyaluronic acid acts as a lubricant and viscosupplement — reducing friction and easing discomfort — but does not contribute to structural repair of a focal lesion. Corticosteroid suppresses inflammation and can settle an acute flare effectively, but its effect is temporary and does not address the defect itself. ChondroFiller is aimed at supporting the body's own repair processes within a contained structural lesion: a different therapeutic intent, suited to a different stage of hip joint disease.

What the clinical evidence shows for the hip

The strongest hip-specific data come from a prospective cohort published by Mazek and colleagues in the Journal of Hip Preservation Surgery in 2021. Twenty-six adults with femoroacetabular impingement and acetabular cartilage lesions exceeding 2 cm² were followed for between one and five years after ChondroFiller treatment. Of the 21 patients evaluable at final review, 17 achieved good or excellent outcomes; only two required total hip replacement during the follow-up window. That 80% good-or-excellent rate is a meaningful signal — but it should be read against the study's scale: a single prospective cohort of 26 patients, no randomised comparator arm, and a maximum follow-up of five years rather than the decade-plus horizon that matters most when a patient in their forties is weighing whether to defer joint replacement.

Pooled estimates across published hip-specific series place meaningful symptom relief at 70–85% in carefully selected patients at one and a half to three years, with reoperation rates of approximately 3–8% in qualified candidates. The primary functional outcome anchor in the hip evidence base is a Modified Harris Hip Score improvement of approximately 30 points — a clinically relevant gain, though derived from the same small European cohort literature rather than from large independent replication.

A qualification that deserves proper attention rather than a brief parenthesis: the Mazek cohort, the pooled estimates, and the Harris Hip Score signal all reflect arthroscopic delivery — ChondroFiller introduced into a surgically prepared joint under general or spinal anaesthesia. The outpatient ultrasound-guided injectable pathway available in current clinical practice is an evolution from that route, designed to make the scaffold accessible without theatre admission or incision. Hip-specific outcome data for the injectable form specifically remain limited at this stage. The biological scaffold and cell-recruitment mechanism are the same — confirmed to function in a fluid-joint environment by the 2025 ex vivo work described earlier — but injectable hip cohorts have not yet replicated the size or follow-up duration of the arthroscopic studies. The arthroscopic evidence is best understood as strongly supporting, rather than directly measuring, the injectable pathway's expected outcomes.

Which patients are realistic candidates

Not every damaged hip is the right type for cartilage preservation — and the decision turns on one central radiological measure: Tönnis grade.

Tönnis grade classifies hip osteoarthritis severity on plain radiograph: Grade 0 is a normal joint, Grade 1 shows minimal changes, Grade 2 indicates moderate established arthritis, and Grade 3 reflects severe degeneration with marked joint-space loss. In the Mazek 2021 cohort, patients with pre-existing Tönnis Grade 2–3 fared poorly; Tönnis below 2 has since become the established selection threshold. The reasoning is direct: patients at Grade 2 or above have generalised joint involvement that a focal scaffold cannot address, and treating them as cartilage preservation candidates would be clinically inappropriate.

The target population occupies a more specific window: younger patients — typically those not yet appropriate for hip replacement — who have focal, well-bordered Grade III or IV acetabular cartilage damage, often associated with femoroacetabular impingement, with healthy surrounding cartilage borders and adequate subchondral bone integrity. The biological repair environment matters as much as the defect itself.

Pre-injection imaging assessment typically includes alpha angle measurement, a validated tool for predicting chondral health grade in FAI patients. A meta-analysis of ten studies involving 447 patients found that alpha angle correlates closely with Outerbridge cartilage deterioration grade — higher angles correspond to more severe damage — helping distinguish candidates for joint preservation from those who may benefit from a different approach.

Diffuse or advanced hip osteoarthritis, characterised by global joint-space loss and bone-on-bone contact at Kellgren-Lawrence Grade IV, is a clear contraindication. ChondroFiller cannot compensate for a hip joint that has essentially worn through. A formal clinical assessment, including imaging review, is required to determine whether a given hip meets these criteria before any injection is considered.

The outpatient injection pathway at Lincolnshire Hip

The procedure itself is a same-day in-clinic appointment: no general anaesthetic, no incision, no theatre admission. A clinical assessment and imaging review precede any injection to confirm that the joint meets the selection criteria outlined above; patients whose osteoarthritis has progressed beyond the treatment's scope are counselled toward alternative options rather than offered an injection that is unlikely to benefit them.

Image guidance is a clinical requirement, not a preference, for hip injection. The femoral artery runs approximately 1.9 cm medial to the joint capsule, with the femoral nerve 2.3 cm lateral — anatomy that makes accurate placement with landmark technique alone unreliable. Hoeber and colleagues' 2016 systematic review, covering 120 studies, found that landmark-guided hip injections achieved accurate intra-articular placement in only 72% of cases (95% CI 56–85%), compared with 100% for image-guided techniques (95% CI 98–100%), a difference significant at p<0.0001. Ultrasound guidance removes that margin of error.

After injection, a period of protected weight-bearing is required while the collagen scaffold stabilises within the joint. A 2024 biomechanical study confirmed that full loading in the immediate post-procedure period can prevent the gel from adequately cushioning opposing cartilage; reduced activity in the initial weeks allows the matrix to consolidate before normal hip loading resumes. Patients should plan for this phase when timing the appointment around work or other commitments.

Because ChondroFiller's window of benefit narrows as osteoarthritis advances — Tönnis Grade 2 today may cross the candidacy threshold within months — earlier assessment carries genuine clinical value. Lincolnshire Hip is part of the MSK Doctors group and accepts patients without GP referral for hip assessment, with appointments at Sleaford and Grantham.

When hip replacement remains the right answer

For patients who have reached Tönnis Grade 2–3 or show diffuse joint-space loss at Kellgren-Lawrence Grade IV, hip replacement is not a fallback position — it is the appropriate clinical answer, and framing it otherwise does those patients a disservice.

Total hip replacement has a robust long-term record. Approximately 58% of implants are estimated to last 25 years, giving most patients who receive one in middle age a high probability of a single, definitive procedure that resolves rather than manages end-stage joint disease. Lincolnshire Hip offers the full replacement pathway, including the SPAIRE and Bikini minimally invasive variants, which aim to preserve the soft-tissue envelope around the hip joint — a practical advantage for recovery and longer-term function.

ChondroFiller and total hip replacement are sequential stages on the same care continuum, not competing treatments. A prior collagen scaffold injection does not foreclose the replacement option for patients who later need it; the joint-preservation window and the surgical pathway run in order, not in opposition.

For patients who are well selected and achieve the 3–5 year deferral that the evidence supports, the clinical value is real and patient-specific: every year without a prosthesis matters most for patients in their forties and fifties, who are statistically more likely to outlive a first implant. The treatment goal in those cases was always a well-timed surgery — not its permanent avoidance.

1. [1] Arthroscopic utilization of ChondroFiller gel for the treatment of hip articular cartilage defects: a cohort study with 12- to 60-month follow-up. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002
2. [2] Development of an Ex Vivo Osteochondral Biomimetic Platform for Mechanistic Investigation of Cartilage Regeneration. (2025). https://doi.org/10.3390/ijms262311759 https://doi.org/10.3390/ijms262311759
3. [3] AB1396 FUTURE OF HIP CARTILAGE PRESERVATION: α Angle Endpoints Optimise Indications for Conservative Care. (2023). https://doi.org/10.1136/annrheumdis-2023-eular.90 https://doi.org/10.1136/annrheumdis-2023-eular.90
4. [4] Influence of cartilage defects and a collagen gel on integrity of corresponding intact cartilage: a biomechanical in-vitro study. (2024). https://doi.org/10.1007/s00402-024-05530-z https://doi.org/10.1007/s00402-024-05530-z